Javascript must be enabled to continue!
Significance of HLA in the development of Graves’ orbitopathy
View through CrossRef
Abstract
Graves’ disease (GD), similarly to most autoimmune disease, is triggered by environmental factors in genetically predisposed individuals. Particular HLA alleles increase or decrease GD risk. No such correlation was demonstrated for Graves’ orbitopathy (GO) in Caucasian population. HLA-A, -B, -C, -DQB1 and -DRB1 genotyping was performed using a high-resolution method in a total number of 2378 persons including 70 patients with GO, 91 patients with non-GO GD and 2217 healthy controls to compare allele frequencies between GO, non-GO and controls. Significant associations between GO and HLA profile were demonstrated, with HLA-A*01:01, -A*32:01, -B*37:01, -B*39:01, -B*42:01, -C*08:02, C*03:02, DRB1*03:01, DRB1*14:01 and DQB1*02:01 being genetic markers of increased risk of GO, and HLA-C*04:01, -C*03:04, -C*07:02 and DRB1*15:02 being protective alleles. Moreover, correlations between HLA alleles and increased or decreased risk of non-GO GD, but with no impact on risk of GO development, were revealed. Identification of these groups of GO-related and GO-protective alleles, as well as the alleles strongly related to non-GO GD, constitutes an important step in a development of personalized medicine, with individual risk assessment and patient-tailored treatment.
Springer Science and Business Media LLC
Title: Significance of HLA in the development of Graves’ orbitopathy
Description:
Abstract
Graves’ disease (GD), similarly to most autoimmune disease, is triggered by environmental factors in genetically predisposed individuals.
Particular HLA alleles increase or decrease GD risk.
No such correlation was demonstrated for Graves’ orbitopathy (GO) in Caucasian population.
HLA-A, -B, -C, -DQB1 and -DRB1 genotyping was performed using a high-resolution method in a total number of 2378 persons including 70 patients with GO, 91 patients with non-GO GD and 2217 healthy controls to compare allele frequencies between GO, non-GO and controls.
Significant associations between GO and HLA profile were demonstrated, with HLA-A*01:01, -A*32:01, -B*37:01, -B*39:01, -B*42:01, -C*08:02, C*03:02, DRB1*03:01, DRB1*14:01 and DQB1*02:01 being genetic markers of increased risk of GO, and HLA-C*04:01, -C*03:04, -C*07:02 and DRB1*15:02 being protective alleles.
Moreover, correlations between HLA alleles and increased or decreased risk of non-GO GD, but with no impact on risk of GO development, were revealed.
Identification of these groups of GO-related and GO-protective alleles, as well as the alleles strongly related to non-GO GD, constitutes an important step in a development of personalized medicine, with individual risk assessment and patient-tailored treatment.
Related Results
High Resolution HLA-A, HLA-B, and HLA-C Allele Frequencies in Romanian Hematopoietic Stem Cell Donors
High Resolution HLA-A, HLA-B, and HLA-C Allele Frequencies in Romanian Hematopoietic Stem Cell Donors
The HLA genes are associated with various autoimmune pathologies, with the control of the immune response also being significant in organs and cells transplantation. The aim of the...
Diversity of HLA Class I and II Genes in the North Indian Population
Diversity of HLA Class I and II Genes in the North Indian Population
Introduction: Numerous studies have concentrated on specific populations to explore the extensive polymorphism of class I and II HLA genes. This genetic diversity is crucial for va...
CD34 negative HLA‐DR negative acute myeloid leukaemia: A higher association with NPM1 and FLT3‐ITD mutations
CD34 negative HLA‐DR negative acute myeloid leukaemia: A higher association with NPM1 and FLT3‐ITD mutations
AbstractIntroductionCD34 and HLA‐DR negativity is often used as a characteristic immunophenotypic feature of acute promyelocytic leukaemia (APL) that differentiates APL from other ...
Abstract 1658: Gemcitabine impacts expression of antigen presentation proteins by pancreatic cancer cells
Abstract 1658: Gemcitabine impacts expression of antigen presentation proteins by pancreatic cancer cells
Abstract
Background: Pancreatic adenocarcinoma is one of the deadliest type of cancers with a 5-year overall survival rate of 10%. A standard chemotherapy approach f...
HLA Gene Polymorphisms in Romanian Patients with Chronic Lymphocytic Leukemia
HLA Gene Polymorphisms in Romanian Patients with Chronic Lymphocytic Leukemia
Background and Objectives. Numerous genome-wide association studies have highlighted that chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder with an important gen...
Immunogenetic Background of Chronic Lymphoproliferative Disorders in Romanian Patients—Case Control Study
Immunogenetic Background of Chronic Lymphoproliferative Disorders in Romanian Patients—Case Control Study
Background and Objectives: The implications of the genetic component in the initiation and development of chronic lymphoproliferative disorders have been the subject of intense res...
CD Markers and HLA Expression in Chronic Lymphocytic Leukemia Patients: correlations and clinical relevance
CD Markers and HLA Expression in Chronic Lymphocytic Leukemia Patients: correlations and clinical relevance
Chronic lymphocytic leukemia (CLL) is a distinct category of lymphoproliferative disorder characterized by the clonal expansion of mature B cells, followed by their accumulation in...
The Impact of Anti-HLA Antibodies on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome
The Impact of Anti-HLA Antibodies on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome
Objective To investigate the risk factors of positive anti-HLA antibodies in myelodysplastic syndrome (MDS) patients and gain insights into the impact of anti-HLA antibodies in all...

